% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{AfsharOromieh:126017,
      author       = {A. Afshar-Oromieh$^*$ and E. Avtzi$^*$ and F. L. Giesel$^*$
                      and T. Holland-Letz$^*$ and H. G. Linhart$^*$ and M.
                      Eder$^*$ and M. Eisenhut$^*$ and S. Boxler and B. A.
                      Hadaschik and C. Kratochwil$^*$ and W. Weichert and K.
                      Kopka$^*$ and J. Debus$^*$ and U. Haberkorn$^*$},
      title        = {{T}he diagnostic value of {PET}/{CT} imaging with the
                      (68){G}a-labelled {PSMA} ligand {HBED}-{CC} in the diagnosis
                      of recurrent prostate cancer.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {42},
      number       = {2},
      issn         = {1619-7089},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2017-02132},
      pages        = {197 - 209},
      year         = {2015},
      abstract     = {Since the introduction of positron emission tomography
                      (PET) imaging with (68)Ga-PSMA-HBED-CC
                      (=(68)Ga-DKFZ-PSMA-11), this method has been regarded as a
                      significant step forward in the diagnosis of recurrent
                      prostate cancer (PCa). However, published data exist for
                      small patient cohorts only. The aim of this evaluation was
                      to analyse the diagnostic value of (68)Ga-PSMA-ligand PET/CT
                      in a large cohort and the influence of several possibly
                      interacting variables.We performed a retrospective analysis
                      in 319 patients who underwent (68)Ga-PSMA-ligand PET/CT from
                      2011 to 2014. Potential influences of several factors such
                      as prostate-specific antigen (PSA) level and doubling time
                      (DT), Gleason score (GSC), androgen deprivation therapy
                      (ADT), age and amount of injected tracer were evaluated.
                      Histological verification was performed in 42 patients after
                      the (68)Ga-PSMA-ligand PET/CT. Tracer uptake was measured in
                      901 representative tumour lesions.In $82.8\%$ of the
                      patients at least one lesion indicative of PCa was detected.
                      Tumor-detection was positively associated with PSA level and
                      ADT. GSC and PSA-DT were not associated with
                      tumor-detection. The average maximum standardized uptake
                      value (SUVmax) of tumour lesions was 13.3 ± 14.6
                      (0.7-122.5). Amongst lesions investigated by histology, 30
                      were false-negative in 4 different patients, and all other
                      lesions (n = 416) were true-positive or true-negative. A
                      lesion-based analysis of sensitivity, specificity, negative
                      predictive value (NPV) and positive predictive value (PPV)
                      revealed values of $76.6\%,$ $100\%,$ $91.4\%$ and $100\%.$
                      A patient-based analysis revealed a sensitivity of $88.1\%.$
                      Of 116 patients available for follow-up, 50 received local
                      therapy after (68)Ga-PSMA-ligand PET/CT.(68)Ga-PSMA-ligand
                      PET/CT can detect recurrent PCa in a high number of
                      patients. In addition, the radiotracer is highly specific
                      for PCa. Tumour detection is positively associated with PSA
                      and ADT. (68)Ga-PSMA-ligand PET/CT can help delay systemic
                      therapy of PCa.},
      keywords     = {Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)) (NLM Chemicals) /
                      Oligopeptides (NLM Chemicals) / Radiopharmaceuticals (NLM
                      Chemicals) / Edetic Acid (NLM Chemicals)},
      cin          = {E060 / C060 / G010 / E030 / E050},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)G010-20160331 / I:(DE-He78)E030-20160331 /
                      I:(DE-He78)E050-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25411132},
      pmc          = {pmc:PMC4315487},
      doi          = {10.1007/s00259-014-2949-6},
      url          = {https://inrepo02.dkfz.de/record/126017},
}